Security key
221015100
Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)
CUSIP: 221015100
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 69,974,523
- Total 13F value
- $1,023,112,733
- Share change
- +22,456,136
- Put/Call ratio
- 33%
- SEC-reported price per share
- $14.63
- Number of holders
- 164
- Value change
- +$357,447,187
- Number of buys
- 116
- Number of sells
- 55
- Shares outstanding
- 84,335,427
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
164
Top holders
10
CRVS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Corvus Pharmaceuticals, Inc. SEC filings
Corvus Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 221015100
Recent filing periods:
Ownership snapshot
Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
Sirenia Capital Managemen...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 10%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
10%
Richard A. Miller MD
7.8%
Sirenia Capital Management LP
7.5%
ADAMS STREET PARTNERS LLC
3.9%
BlackRock, Inc.
6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
10%
|
$66,290,001
8,609,091 shares
|
-$9,057,756 | 23 Jan 2026 |
| Richard A. Miller MD |
13D/G
Richard A. Miller
|
7.8%
|
$40,653,959
6,085,922 shares
|
+$5,781,901 | 31 Dec 2025 |
| Sirenia Capital Management LP |
13D/G
|
7.5%
|
$101,657,601
6,831,828 shares
|
$0 | 31 Mar 2026 |
| ADAMS STREET PARTNERS LLC |
13D/G
3/4/5
13F
10%+ Owner · Company
|
3.9%
|
$25,222,243
3,275,616 shares
|
$0 | 23 Jan 2026 |
| BlackRock, Inc. |
13F
Company
|
6%
|
$38,933,979
5,056,361 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
4.6%
|
$29,825,811
3,873,482 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
164
Shares
69,974,523
Rows available
164
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
164
Q1 2026 holders
164
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend